These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 38892472)
1. Small Molecule Therapeutics in the Pipeline Targeting for Triple-Negative Breast Cancer: Origin, Challenges, Opportunities, and Mechanisms of Action. James N; Owusu E; Rivera G; Bandyopadhyay D Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892472 [TBL] [Abstract][Full Text] [Related]
2. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. Qin JJ; Yan L; Zhang J; Zhang WD J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482 [TBL] [Abstract][Full Text] [Related]
3. Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer. Mir MA; Qayoom H; Mehraj U; Nisar S; Bhat B; Wani NA Curr Cancer Drug Targets; 2020; 20(8):586-602. PubMed ID: 32418525 [TBL] [Abstract][Full Text] [Related]
4. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer. Nath A; Mitra S; Mistry T; Pal R; Nasare VD Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991 [TBL] [Abstract][Full Text] [Related]
5. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. Mehlich D; Marusiak AA Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515 [TBL] [Abstract][Full Text] [Related]
6. Triple negative breast cancer: special histological types and emerging therapeutic methods. Cao L; Niu Y Cancer Biol Med; 2020 May; 17(2):293-306. PubMed ID: 32587770 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library. Fujita T; Mizukami T; Okawara T; Inoue K; Fujimori M Breast Cancer; 2014 Nov; 21(6):738-47. PubMed ID: 23456737 [TBL] [Abstract][Full Text] [Related]
9. AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer. Cao W; Li J; Hao Q; Vadgama JV; Wu Y Breast Cancer Res; 2019 Feb; 21(1):29. PubMed ID: 30791936 [TBL] [Abstract][Full Text] [Related]
10. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice. Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724 [TBL] [Abstract][Full Text] [Related]
11. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M; Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662 [TBL] [Abstract][Full Text] [Related]
12. Advances in small-molecule drug discovery for triple-negative breast cancer. Fosu-Mensah N; Peris MS; Weeks HP; Cai J; Westwell AD Future Med Chem; 2015; 7(15):2019-39. PubMed ID: 26495746 [TBL] [Abstract][Full Text] [Related]
13. Identification of a small molecule as inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells. Ding Y; Chen X; Liu C; Ge W; Wang Q; Hao X; Wang M; Chen Y; Zhang Q J Hematol Oncol; 2021 Jan; 14(1):19. PubMed ID: 33472669 [TBL] [Abstract][Full Text] [Related]
14. Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting. Williams CB; Soloff AC; Ethier SP; Yeh ES Adv Cancer Res; 2015; 127():253-81. PubMed ID: 26093903 [TBL] [Abstract][Full Text] [Related]
15. Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer. Islam R; Lam KW Eur J Med Chem; 2020 Dec; 207():112812. PubMed ID: 32937283 [TBL] [Abstract][Full Text] [Related]
16. A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction. Park SK; Byun WS; Lee S; Han YT; Jeong YS; Jang K; Chung SJ; Lee J; Suh YG; Lee SK Biochem Pharmacol; 2020 Aug; 178():114053. PubMed ID: 32450253 [TBL] [Abstract][Full Text] [Related]
17. A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways. Matossian MD; Burks HE; Elliott S; Hoang VT; Zuercher WJ; Wells C; Drewry DH; Kapadia N; Chang T; Yan T; Windsor GO; Nguyen K; Fang F; Nephew KP; Buechlein A; Rusch DB; Sabol RA; Ucar DA; Zabaleta J; Miele L; Bunnell BA; Collins-Burow BM; Burow ME Anticancer Drugs; 2020 Sep; 31(8):759-775. PubMed ID: 32796402 [TBL] [Abstract][Full Text] [Related]
18. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335 [TBL] [Abstract][Full Text] [Related]
19. The evolving management of metastatic triple negative breast cancer. Malhotra MK; Emens LA Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561 [TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. Ferrari P; Scatena C; Ghilli M; Bargagna I; Lorenzini G; Nicolini A Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163586 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]